Summary This paper examines the expression of fibroblast growth factor 2 (FGF-2) in the malignant human breast. Semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to assess the level of expression of FGF-2 in a series of 51 patients clinically followed up for a median of 84 months (Luqmani et al, 1992 
The fibroblast growth factors (FGFs) form a family of nine identified growth-regulatory proteins that share 35-50% overall homology and induce proliferation and differentiation of a wide range of cells of epithelial, mesodermal and neuroectodermal origin ; Basilico and Moscatelli, 1992 ; Klagsbrun, 1989) . All except FGF-l and FGF-2 are synthesized with an N-terminal hydrophobic signal sequence, enabling the classical mechanism of secretion from cells (Abraham et al, 1986; Jaye et al, 1986) . Release of FGF-1 and FGF-2 may occur through leakage from damaged cells or from viable cells through a novel mechanism (Mignatti et al, 1992) . FGF-2 has diverse biological functions, which include involvement in cellular growth, differentiation, embryogenesis, wound healing, plasminogen activator synthesis, invasion and angiogenesis (Montesano et al, 1986; Gospodarowicz et al, 1987; Sato and Rifkin, 1988 ; Klagsbrun, 1989; . Several of these functions could influence the progression of cancer by encouraging cell growth or metastasis, and FGFs have consequently been studied in several cancers.
FGF-2 has been detected in a variety of human cancers, including colonic adenocarcinoma (New and Yeoman, 1992) , bladder cancer (Allen and Maher, 1993) , rhabdomyosarcoma , ovarian cancer (Crickard et al, 1994) , pancreatic carcinoma (Leung et al, 1994) , renal cell carcinoma (Emoto et al, 1994) and oesophageal carcinoma (lida et al, 1994) . Studies of human breast have shown high levels of FGF-2 mRNA in non-malignant breast, with malignant transformation of epithelial cells leading to reduced expression (Luqmani et al, 1992; Anandappa et al, 1994) . However, both studies showed that about one in four cancers expressed FGF-2 mRNA at levels similar to those found in the benign tissue. A similar pattern is seen for FGF-1 expression in the breast, as lower amounts of FGF-1 and FGF-1 mRNA were found in malignant breast tissue than in nonmalignant breast tissue . The principal source of FGF-2 in the breast appears to be myoepithelial cells. FGF-2 mRNA has been detected in both epithelial and myoepithelial breast cells, with the latter expressing higher levels (Ke et al, 1993) . Immunohistochemical studies using paraffin sections have shown that FGF-2 localizes to myoepithelial cells and the basement membrane in benign breast biopsies and intraduct carcinomas (Gomm et al, 1991) .
The cellular response to FGF-2 is mediated through the formation of a trimolecular complex composed of FGF-2, one of the high-affinity FGF receptors (FGFR) and an extracellular matrix or cell-surface heparan sulphate proteoglycan (Yayon et al, 1991) . A family of four high-affinity receptors encoded by separate genes has been identified, and the complexity of this family is enhanced by an array of spliced variants (Jaye et al, 1992) . The principal high-affinity receptors for FGF-2 appear to be FGFR-1 and one of the splice variants of FGFR-2 (FGFR-2-IIIC) (Mansukhani et al, 1992; Werner et al, 1992) . FGFR-3 and FGFR-4 bind to FGF-2 with lower affinity (Ron et al, 1993; Chellaiah et al, 1994) . Both FGFR-1 and the IlIc variant of FGFR-2 are present in breast cancers (Luqmani et al, 1992; Penault-Llorca et al, 1995) . The relative level of the beta (2-immunoglobulin-like domain) form compared with the alpha (3-immunoglobulin-like domain) form of FGFR-1 is higher in malignant breast biopsies . The beta form of FGFR-1 has been reported to have a higher affinity for FGF-2, indicating that breast cancer cells may *Present address: Faculty of Allied Health Sciences, Kuwait University, PO Box 31470, Kuwait FGF-2 in breast cancer 29 bind efficiently to any available FGF ligand (Shi et al, 1993) . Amplification of the FGFR-1 and FGFR-2 genes has been observed in 12.7% and 11.5% of 387 breast cancers respectively (Adnane et al, 1991) . Several studies mentioned above have shown that FGF-2 mRNA is present in generally lower quantities in human breast cancer than in non-malignant tissue. We have extended these studies and report here that FGF-2 protein reflects this trend, with generally lower amounts being detectable in malignant tissues. We have also used previously obtained data on FGF-2 mRNA levels in breast cancers to investigate whether FGF-2 expression may be a prognostic indicator. We find that low expression of FGF-2 mRNA correlates with decreased disease-free and overall survival. 100%) for 5 min. Sections were washed in PBS (pH 7.2) and blocked for endogenous biotin, following the protocol included with a biotin blocking kit (Vector Labs). After three further washes in PBS, sections were preincubated with normal goat serum (15% in PBS with 5% bovine serum albumin) for 30 min at room temperature. After discarding the preincubation buffer, sections were incubated ovemight at 4°C with a rabbit polyclonal antibody to FGF-2 (0.5 jg ml-') (a kind gift from Dr A Baird) or non-immune rabbit IgG at an equivalent concentration, diluted in PBS containing 15% goat serum and 5% bovine serum albumin (BSA). As a further control, FGF-2 was used as an antigen block. FGF-2 (5 jig ml-') was preincubated with rabbit polyclonal antibody to FGF-2 (0.25 jg ml-') for 16 h at 4°C before an ovemight incubation on the section at 4°C. The next day, sections were washed in PBS and incubated in biotinylated anti-rabbit IgG second antibody diluted 1:200 in PBS containing 10% human serum for 30 min at room temperature. Sections were washed in PBS and incubated for a further 1 h at room temperature in Vectastain ABC reagent (Vector Labs). Immunoproduct was visualized using 0.05% 3, 3-diaminobenzidine and sections counterstained with Gill's haematoxylin.
MATERIALS AND METHODS Patients and tissue samples

Statistical analysis
We have previously studied the expression of FGF-2 mRNA in a Tissue extraction panel of 66 breast cancer tissues, using a semiquantitative RT-PCR After histological confirmation of the diagnosis, a portion of the tissue was pulverized to a fine powder, and cellular RNA was extracted using the guanidium isothiocyanate procedure (Chirgwin et al, 1979) . For protein analysis the tissues were lysed in phosphate-buffered saline (PBS) containing 1% NP40, 0.1% sodium dodecyl sulphate (SDS), 100 jig ml-' phenylmethylsulphonyl fluoride (PMSF) and 5 jig ml-aprotinin and then mixed with an equal volume of SDS-PAGE sample buffer containing 2-mercaptoethanol.
SDS-PAGE and Western blotting
Aliquots of lysate containing 40 jg of protein were electrophoresed through a 15% polyacrylamide gel. The separated proteins were transferred onto nitrocellulose membranes for 3 h at 200 mA. The blots were blocked with 3% milk powder in PBS containing 0.1% Tween 20 (PBS-T) for 1 h, incubated with polyclonal rabbit anti-FGF-2 antibody directed against amino acids 1-24 (a generous gift from Dr A Baird) (Emoto et al, 1989) for 1 h and finally incubated for a further hour with an anti-rabbit IgG antibody conjugated to horseradish peroxidase (Sigma). After five washes with PBS-T, bands were visualized using the enhanced chemoluminescence (ECL) method (Amersham, UK). To ensure that approximately the same number of epithelial cells were loaded in each lane, a monoclonal antibody against the epithelial marker cytokeratin 18 (Sigma), followed by an anti-mouse-horseradish peroxidase conjugate, was also used to probe the nitrocellulose membrane.
Immunohistochemistry
Breast tissue biopsies were immediately snap frozen in liquid nitrogen. Tissue sections (8-10 jm) were cut and mounted on coated slides. Immunostaining was performed using a three-stage avidin-biotin complex (ABC) immunoperoxidase technique. Briefly, frozen sections were fixed in 3.7% formaldehyde in PBS for 10 min and permeabilized in ice-cold acetone (50% followed by (Luqmani et al, 1992) . Mean values of 4.25 and 0.87 were found in non-malignant and cancer tissues respectively, and there is a significant difference between levels of FGF-2 mRNA expression in the two groups (P < 0.0001) method (Luqmani et al, 1992) . The clinical progress of 51 of these patients has been followed for up to 10 years, and we are now in a position to analyse the effect of variation in FGF-2 mRNA expression on disease-free and overall survival. Univariate survival analyses were performed for overall and disease-free survival. Cases were divided into high and low FGF-2 expressors using the median value as the cut-off point. Survival curves were constructed using the Kaplan-Meier method. Significance was calculated using the log-rank test. In order to assess the effect of other confounding variables on survival, Cox's proportional hazards model was used and included terms for FGF-2, T stage and nodal status.
RESULTS
Prognostic value of FGF-2 mRNA
We have previously studied the level of FGF-2 mRNA in a panel of human breast tumours (Luqmani et al, 1992) . We found significantly higher levels of FGF-2 mRNA in non-malignant breast tissues (mean value 4.25) than in breast cancers (mean value 0.87) ( Figure  1) . Fifty-one patients from the original study have now been followed up for a median time of 84 months. Details of these Table 1 . We are now able to examine the possibility that FGF-2 mRNA could provide prognostic information. Overall and disease-free survival analyses were performed by dividing patients into two equal groups, using the median value of FGF-2 mRNA expression as the cut-off point. Kaplan-Meier survival plots show that higher levels of FGF-2 mRNA are associated with improved overall and disease-free survival (Figure 2) . Univariate log-rank analyses showed that these differences were significant, giving P-values of 0.040 for overall survival and 0.022 for disease-free survival. The effect of T stage and nodal status on confounding variables was also tested using Cox's proportional hazards model. In this analysis, FGF-2 remains a significant predictor of good disease-free survival (P = 0.028), although not of overall survival (P = 0.061). However, there was no significant correlation between FGF-2 expression and oestrogen receptor status.
Western blotting experiments on human breast tissues Our previous results obtained using RT-PCR analysis had shown generally lower amounts of FGF-2 mRNA in breast cancer than in non-malignant breast tissues (Luqmani et al, 1992) . We wished to determine whether the level of FGF-2 protein in malignant samples was also generally lower than in non-malignant samples. We made lysates of tissues and used Westem analysis to determine FGF-2 British Journal of Cancer (1997) 
Immunohistochemistry of breast cancer sections
Frozen tissues from 15 cases of invasive carcinoma and one case of ductal carcinoma in situ (DCIS) from the original RT-PCR study were available for investigation by immunohistochemistry. These samples and a further eight samples shown in group 2 of Table 1 plus six additional DCIS tissues were investigated for FGF-2 staining by immunohistochemistry. Previously, using paraffin sections, we were unable to demonstrate the presence of immunostainable FGF-2 in neoplastic breast epithelial cells (Gomm et al, 1991) . However, using a different protocol on frozen sections, FGF-2 staining could be seen in cancer tissues as well as non-malignant tissues. The primary antibody used has previously been shown to be specific for FGF-2 (Gomm et al, 1991) . The results of staining are shown in Figure 4 and Table 2 . Figure 4 demonstrates the reduction in FGF-2 expression in cancer using two breast cancer sections that contain adjacent normal ducts. The normal ducts of both sections show intense FGF-2 staining of the nucleus and cytoplasm of both myoepithelial and epithelial cells. The breast cancer cells show a much lower level of FGF-2 expression, with the section in Figure 4A having reduced levels of FGF-2 and the section in Figure 4B containing almost no FGF-2 in the breast cancer cells. Controls using the same concentration of rabbit IgG or anti-FGF-2 preincubated with FGF-2 were clear. In ten sections of reduction mammoplasty tissue, similarly intense staining of both myoepithelial and epithelial cells was seen (results not shown). In the tumour samples studied, FGF-2 staining was generally lighter. Tumour cells in all three invasive lobular carcinoma examined were negative. In invasive ductal carcinoma, eight cases were negative, while the remaining 12 cases showed heterogeneous and mostly weak or moderate staining (+, ++), with the exception of one case in which the degree of nuclear staining in the neoplastic cells was equal in intensity to that seen in the normal epithelial component ( (Luqmani et al, 1992) in which we reported lower levels of FGF-2 mRNA in breast carcinoma extracts than in extracts of normal breast tissue. The observed decrease in FGF-2 expression in breast cancers may partly be due to the loss of myoepithelial cells that occurs in malignant disease. However, our immunohistochemical analysis shows that the level of FGF-2 staining in luminal epithelial cells also decreases. This decrease in expression is seen quite early in disease, with DCIS sections showing this effect as well as invasive cancers. Statistical analysis of FGF-2 expression levels on tumour samples studied by semiquantitative RT-PCR analysis and immunohistochemistry also indicate that breast carcinomas synthesizing FGF-2 are less aggressive than those that do not. This is reflected in increased disease-free and overall survival for tumours expressing higher levels of FGF-2. This is, to our knowledge, the first report showing immunohistochemical staining for FGF-2 in human breast luminal epithelial cells. Our immunohistochemistry results using frozen sections gave a different staining pattem from that in previously published work using paraffin sections (Gomm et al, 1991) . Whereas previously FGF-2 had been found in myoepithelial cells, frozen sections clearly show expression in luminal epithelial cells as well. The presence of FGF-2 in epithelial cells is confirmed by other studies in which mRNA encoding FGF-2 and FGF-2 protein have been found in human breast epithelial cell lines (Li and Shipley, 1991; Ke et al, 1993; Penault-Llorca et al, 1995) . The effect of different fixation protocols on the location of FGF-2 staining has been well documented (Healy et al, 1992; Ishigooka et al, 1992) . In our hands, FGF-2 staining in epithelial cells is easily lost when tissues are embedded in paraffin or subjected to organic solvent fixation. For instance, the use of acetone rather than formaldehyde fixation on frozen sections led to a loss of FGF-2 staining in epithelial cells but not in myoepithelial cells or basement membrane. Binding of FGF-2 to proteoglycans is known to stabilize the growth factor, and it is possible that the binding of FGF-2 to the basement membrane and proteoglycans on the surface of myoepithelial cells results in the relative stability of FGF-2 staining at these positions.
The role of FGF-2 in breast carcinoma cells is unclear, as is the significance of its down-regulation. In the normal breast, much of the FGF-2 appears to derive from the myoepithelial cells not only in humans (Ke et al, 1993) , but also in rat (Barraclough et al, 1990) and mouse (Coleman-Krnacik and Rosen, 1994) . It may play some role as a survival factor; our results indicate that FGF-2 promotes survival of breast epithelial cells in vitro (JJ Gomm et al, unpublished results) . Carcinoma cells may have lost their dependence on FGF-2 for survival. Cell proliferation experiments suggest that FGF-2 has only a slight stimulatory effect on the growth of breast cancer cell lines (Valverius et al, 1990; Smith et al, 1994; Johnston et al, 1995) . Others have found inhibition of breast cancer cell growth by FGF-2 (McLeskey et al, 1994) . This may suggest that FGF-2 has a role in maintaining the differentiated state of the duct rather than promoting cell proliferation. This is consistent with the high levels of FGF-2 that we have shown to be present in the normal breast. If this is the case, then loss of FGF-2 might lead to more aggressive tumours and the decreased disease-free and total survival seen in this study.
Alternatively, loss of FGF-2 expression may not be causal in increasing the malignancy of breast cancer cells but may be a marker of less differentiated cancers. Breast cancer cells which have lost epithelial markers have been shown to be more invasive, and this could result in decreased disease-free survival (Thompson et al, 1992) .
Measurement of FGF-2 expression in breast cancer may have some role as a prognostic indicator as, in our small series, we found that breast carcinomas with high FGF-2 levels have a better outcome than those that have low levels. However, these preliminary results need confirming in a larger series. We will compare the level of FGF-2 expression with that of other putative prognostic parameters, including oestrogen and progesterone receptor, c-erbB-2 and EGF receptor (Gullick, 1990; Nicholson, 1990) , and correlate this with response to endocrine and cytotoxic therapy. ABBREVIATIONS FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; RT-PCR, reverse transcriptase-polymerase chain reaction; DCIS, ductal carcinoma in situ.
